World Pneumonia Day 2022
World Pneumonia Day, established in 2009, takes place each year on November 12th. The goal is to raise awareness and generate action on combatting pneumonia and to promote interventions to prevent and treat the infectious respiratory disease. Pneumonia is associated with high mortality, especially among young children and the elderly. In 2021, the estimated burden of deaths from respiratory infections, including COVID-19, is 6 million. Through its various consortia and trials, COMBACTE is researching pathogens and identifying possible new interventions for patients with or at risk of developing (ventilator-associated or hospital-acquired) pneumonia.
SAATELLITE-2
SAATELLITE-2 is a phase 3, randomized, double-blind, placebo-controlled, single-dosed trial, focusing on human monoclonal antibody suvratoxumab (AR-320) against Staphylococcus aureus alpha toxin in mechanically ventilated adult and adolescent subjects. SAATELLITE-2 involves patients who are in the ICU at high risk of developing nosocomial pneumonia caused by S. aureus.
In the previous Phase 2 SAATELLITE study, suvratoxumab has been shown to exhibit a favourable safety profile and was associated with a reduction in S. aureus ICU pneumonia and shorter duration of ICU and hospital stays
HONEST-PREPS
HOspital NEtwork STudy – Preparation for a Randomized Evaluation of anti-Pneumonia Strategies (HONEST-PREPS) is a prospective, observational, multicenter cohort study. The aim of the HONEST-PREPS is to set up an infrastructure to prospectively enrol patients at risks of hospital acquired and ventilator associated pneumonia (HAP/VAP) in the ICU. Collected data will be used to inform future diagnostic, preventative and therapeutic trials and to determine the incidence, microbiological etiology (including antibiotic resistance), management and outcome of HAP/VAP in the ICU.
Eight sites that performed well in HONEST-PREPS are currently starting up in ECRAID-Base Perpetual Observational Study into Ventilator Associated Pneumonia (POS-VAP) with the prospect of joining future Randomized Controlled Trials.
ASPIRE-ICU
The ASPIRE-ICU study is a prospective, observational, multicentre, epidemiological cohort study. Nested within routine surveillance among ICU patients in Europe, it focused on estimating the incidence of Staphylococcus aureus and Pseudomonas aeruginosa ICU pneumonia, especially ventilator-associated pneumonia (VAP). The key findings were published in JAMA Network Open and Nature Communications.
STAT-NET
STAT-Net has worked on a systematic review to determine the description of populations and endpoints of randomized clinical trials (RCTs) evaluating antimicrobials for treatment of HAP/VAP in the ICU, as well as other studies involving pneumonia on the ICU.
COVID-19 TRIALS
Since the beginning of the pandemic, COMBACTE has supported many COVID-19 trials by putting forward its network of hospitals and laboratories. Trials include the SOS-COVID and MERMAIDS ARI studies as part of the RECOVER consortium, but also other studies such as BRACE or REMAP-CAP.
You can read more about the various COVID-19 trials COMBACTE is supporting here.
RESULTS
Results of the research on pneumonia done within COMBACTE are collected in almost 40 scientific papers published in journals such as The Lancet Infectious Diseases, Nature Communications, BMC Infectious Diseases, JAMA Network Open, and Critical Care. You can find some of these articles below, but for a full overview you can search the COMBACTE publication library.
1. Vlaeminck, J., Raafat, D., Surmann, K., Timbermont, L., Normann, N., Sellman, B., van Wamel, W.J., Malhotra-Kumar, S.. Exploring Virulence Factors and Alternative Therapies against Staphylococcus aureus Pneumonia. Toxins 2020, 12, 721.
2. Weiss E, Essaied W, Adrie C, Zahar J, Timsit J. Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trials. Critical Care (2017) 21:162.
3. François B, Jafri HS, Chastre J, Sánchez-García M, Eggimann P, Dequin PF, Huberlant V, Viña Soria L, Boulain T, Bretonnière C, et al. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. The Lancet Infectious Diseases , 2021, ISSN 1473-3099.
4. Van Der Schalk, T. E., Coppens, J, Timbermont, L, Turlej-Rogacka, A, Van Heirstraeten, L, Berkell, M, Yu, L, Lammens, C, Britto Xavier, B, Matheeussen, V, et al. Evaluation of GeneXpert PA assay compared to genomic and (semi-)quantitative culture methods for direct detection of Pseudomonas aeruginosa in endotracheal aspirates. Antimicrob Resist Infect Control 10, 110 (2021).
Related updates
“We Take Bigger Steps Together”
COMBACTE's Last General Assembly
COMBACTE Launches Last Magazine
COMBACTE launched its last magazine at ECCMID 2023 in Copenhagen. The magazine focuses on project’s impact, and features articles and interviews with ...